Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.
autologous stem cell transplantation (ASCT)
ixazomib
multiple myeloma
stem cell mobilization
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Jan 2023
09 Jan 2023
Historique:
received:
07
12
2022
revised:
27
12
2022
accepted:
28
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
(1) Background: High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard consolidation strategy for patients with newly diagnosed multiple myeloma (MM) and for a subset of patients with relapsed/refractory disease. For stem cell mobilization, G-CSF alone or in combination with chemotherapy mobilizing agents and/or plerixafor are commonly used. Ixazomib is an oral proteasome inhibitor with less neurotoxic potential, which previously showed the ability to mobilize stem cells in preclinical studies. (2) Methods: Prospective single-center phase 1 study assessing the efficacy and safety of stem cell mobilization with ixazomib and G-CSF in patients with newly diagnosed or relapsed/refractory MM undergoing HDCT and ASCT. Primary endpoint was percentage of patients achieving a yield of at least 6.0 × 10
Identifiants
pubmed: 36672379
pii: cancers15020430
doi: 10.3390/cancers15020430
pmc: PMC9856560
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Hematol. 2020 Dec;112(6):835-840
pubmed: 32876851
Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):e588-e593
pubmed: 31358485
Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):200-205
pubmed: 30679106
Leuk Res. 2015 Jul;39(7):786-92
pubmed: 25891070
Bone Marrow Transplant. 2003 May;31(9):747-54
pubmed: 12732880
Ann Hematol. 2021 Feb;100(2):563-573
pubmed: 33404694
Panminerva Med. 2020 Dec;62(4):220-224
pubmed: 32955179
Swiss Med Wkly. 2019 Apr 03;149:w20031
pubmed: 30943308
Exp Hematol. 2021 May;97:21-31
pubmed: 33617894
JAMA. 2022 Feb 01;327(5):464-477
pubmed: 35103762
J Clin Oncol. 2021 Aug 1;39(22):2430-2442
pubmed: 34111952
Leuk Lymphoma. 2016 May;57(5):1122-9
pubmed: 26294015
Bone Marrow Transplant. 2012 Sep;47(9):1154-63
pubmed: 21874064
Panminerva Med. 2020 Dec;62(4):193-206
pubmed: 32957744
Am J Hematol. 2006 Jun;81(6):426-31
pubmed: 16680735
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Haematologica. 2002 Nov;87(11):1157-64
pubmed: 12414345
Curr Pharm Des. 2008;14(20):1950-61
pubmed: 18691106
BMC Cancer. 2018 Aug 15;18(1):820
pubmed: 30111286
Cytotherapy. 2007;9(6):539-47
pubmed: 17882718
Leuk Lymphoma. 2017 May;58(5):1076-1083
pubmed: 27736269
Ther Adv Hematol. 2017 Jul;8(7):209-220
pubmed: 28694935
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Bone Marrow Transplant. 2016 Mar;51(3):372-6
pubmed: 26437056
Stem Cell Res Ther. 2022 Mar 22;13(1):123
pubmed: 35317856
Transplant Cell Ther. 2021 Jul;27(7):590.e1-590.e8
pubmed: 33915323
Br J Haematol. 1995 Oct;91(2):275-84
pubmed: 8547062
Blood. 2009 Aug 27;114(9):1729-35
pubmed: 19561323
Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195
pubmed: 29410180
Biol Blood Marrow Transplant. 2020 May;26(5):876-883
pubmed: 31785375
Biol Blood Marrow Transplant. 2018 Apr;24(4):694-699
pubmed: 29246820
Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80
pubmed: 25278456
Blood Rev. 2021 May;47:100771
pubmed: 33213986
Bone Marrow Transplant. 1997 Aug;20(3):211-7
pubmed: 9257889
Z Orthop Unfall. 2017 Oct;155(5):575-586
pubmed: 28806822
Transplant Cell Ther. 2021 Sep;27(9):770.e1-770.e7
pubmed: 34153504
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Bone Marrow Transplant. 2020 Oct;55(10):2047-2051
pubmed: 32214229
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308
pubmed: 24141007
Blood. 2018 Jun 7;131(23):2594-2596
pubmed: 29695518
Blood Cancer J. 2019 Apr 8;9(4):44
pubmed: 30962422
J Clin Apher. 2018 Jun;33(3):357-370
pubmed: 28980709
Blood. 2014 Oct 23;124(17):2752-4
pubmed: 25342668
Hematol Oncol. 2022 Aug 3;:
pubmed: 35920140